{"contentid": 488718, "importid": NaN, "name": "Xeris to acquire Strongbridge Biopharma in stock and CVR transaction", "introduction": "US specialty drug company Xeris Pharmaceuticals has entered into a definitive agreement to acquire Strongbridge Biopharma for stock and contingent value rights (CVRs), aiming to create an innovative leader in endocrinology and rare diseases.", "content": "<p>US specialty drug company Xeris Pharmaceuticals (Nasdaq: XERS) has entered into a definitive agreement to acquire Strongbridge Biopharma (Nasdaq: SBBP) for stock and contingent value rights (CVRs), aiming to create an innovative leader in endocrinology and rare diseases.</p>\n<p>The deal values Strongbridge at around $267 million, based on the closing price of Xeris common stock of $3.47 on May 21 and Strongbridge&rsquo;s fully diluted share capital. Strongbridge shares jumped more than 14% to $2.75 in early trading today, while Xeris dipped 3.55 to $3.35 on the announcement.</p>\n<p>The transaction, which has been unanimously approved by the boards of directors of both companies, with the exception of Dr Jeffrey Sherman, a director in common to both companies, who abstained from the voting, is expected to close early in the fourth quarter of 2021, subject to the satisfaction of closing conditions. Upon close of the transaction, the businesses of Xeris and Strongbridge will be combined under a new entity to be called Xeris Biopharma Holdings.</p>\n<p>Under the terms of the agreement at closing, Strongbridge shareholders will receive a fixed exchange ratio of 0.7840 shares of Xeris Biopharma Holdings common stock for each Strongbridge ordinary share they own. Based on the closing price of Xeris common stock on May 21, 2021, this represents approximately $2.72 per Strongbridge ordinary share and a 12.9% premium to the closing price of Strongbridge ordinary shares on May 21, 2021.</p>\n<h2><strong>Triggering events</strong></h2>\n<p>Strongbridge shareholders will also receive 1 non-tradeable CVR for each Strongbridge ordinary share they own, worth up to an additional $1.00 payable in cash or Xeris Biopharma Holdings common stock (at Xeris Biopharma Holdings&rsquo; election) upon achievement of the following triggering events:</p>\n<ul>\n<li>the listing of at least one issued patent for Keveyis (dichlorphenamide) in the US Food and Drug Administration&rsquo;s Orange Book by the end of 2023 or at least $40 million in Keveyis annual net sales in 2023 ($0.25 per ordinary share;</li>\n<li>(ii) achievement of at least $40 million in Recorlev (levoketoconazole) annual net sales in 2023 ($0.25 per ordinary share); and</li>\n<li>(iii) achievement of at least $80 million in Recorlev annual net sales in 2024 ($0.50 per ordinary share). The minimum payment on the CVR per Strongbridge ordinary share is zero and the maximum payment is $1.00 in cash or Xeris Biopharma Holdings common stock, at Xeris Biopharma Holdings&rsquo; election.</li>\n</ul>\n<p>Upon close of the transaction, current Xeris shareholders are expected to own around 60% of the combined company, while current Strongbridge shareholders about 40%.</p>\n<p>&ldquo;This is a very compelling transaction that will create a scalable and diversified biopharmaceutical company increasingly oriented toward more specialty and rare disease products, positioning us for long-term product development and commercial success,&rdquo; said Paul Edick, chairman and chief executive of Xeris.</p>\n<p>&ldquo;Strongbridge&rsquo;s attractive rare disease portfolio and capabilities are highly complementary with Xeris. Building on the continuing prescription growth of Gvoke [glucagon] with an enhanced and diversified growth profile, expanded and scalable salesforce, and expected cost-synergies, the combined company will be well positioned to deliver compelling long-term value to shareholders. We look forward to welcoming the Strongbridge team to Xeris and leveraging our differentiated portfolios and technologies to help the patients we serve improve their quality of life,&rdquo; he added.</p>", "date": "2021-05-24 16:47:00", "meta_title": "Xeris to acquire Strongbridge Biopharma in stock and CVR transaction", "meta_keywords": "Xeris Pharmaceuticals, Strongbridge Biopharma, Acquisition, M&A, Keveyis, Recorlev", "meta_description": "Xeris to acquire Strongbridge Biopharma in stock and CVR transaction", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-24 16:44:09", "updated": "2021-05-24 16:52:51", "access": NaN, "url": "https://www.thepharmaletter.com/article/xeris-to-acquire-strongbridge-biopharma-in-stock-and-cvr-transaction", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "xeris_pharmaceuticals_big.jpg", "image2id": "xeris_pharmaceuticals_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Endocrinology, Rare diseases", "topic_tag": "Companies, mergers and acquisitions, One to Watch Companies", "geography_tag": "USA", "company_tag": "Strongbridge Biopharma, Xeris Pharmaceuticals", "drug_tag": "Keveyis, Recorlev", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-24 16:47:00"}